Kennedy Investment Group Has $268,000 Stake in Thermo Fisher Scientific Inc. (NYSE:TMO)

Kennedy Investment Group reduced its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 5.0% during the third quarter, Holdings Channel.com reports. The firm owned 433 shares of the medical research company’s stock after selling 23 shares during the quarter. Kennedy Investment Group’s holdings in Thermo Fisher Scientific were worth $268,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of the company. James Hambro & Partners LLP lifted its holdings in shares of Thermo Fisher Scientific by 5.7% in the 3rd quarter. James Hambro & Partners LLP now owns 209,453 shares of the medical research company’s stock worth $129,524,000 after purchasing an additional 11,276 shares in the last quarter. Castleview Partners LLC lifted its stake in Thermo Fisher Scientific by 2.2% during the 3rd quarter. Castleview Partners LLC now owns 1,656 shares of the medical research company’s stock valued at $1,024,000 after acquiring an additional 36 shares in the last quarter. MBE Wealth Management LLC lifted its stake in Thermo Fisher Scientific by 2.6% during the 3rd quarter. MBE Wealth Management LLC now owns 1,278 shares of the medical research company’s stock valued at $791,000 after acquiring an additional 32 shares in the last quarter. Bellecapital International Ltd. lifted its stake in Thermo Fisher Scientific by 7.4% during the 3rd quarter. Bellecapital International Ltd. now owns 10,168 shares of the medical research company’s stock valued at $6,290,000 after acquiring an additional 703 shares in the last quarter. Finally, Arlington Partners LLC increased its position in shares of Thermo Fisher Scientific by 18.8% during the 3rd quarter. Arlington Partners LLC now owns 6,651 shares of the medical research company’s stock valued at $4,114,000 after purchasing an additional 1,053 shares during the last quarter. 89.23% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on the company. JPMorgan Chase & Co. raised their target price on Thermo Fisher Scientific from $650.00 to $670.00 and gave the company an “overweight” rating in a research report on Friday, September 20th. Wells Fargo & Company started coverage on Thermo Fisher Scientific in a research report on Tuesday, August 27th. They set an “overweight” rating and a $670.00 target price for the company. Robert W. Baird lifted their price objective on Thermo Fisher Scientific from $620.00 to $632.00 and gave the stock an “outperform” rating in a report on Thursday, July 25th. Bank of America lifted their target price on Thermo Fisher Scientific from $600.00 to $675.00 and gave the company a “buy” rating in a report on Monday, September 16th. Finally, TD Cowen lifted their price target on Thermo Fisher Scientific from $648.00 to $658.00 and gave the company a “buy” rating in a research report on Thursday, July 25th. Four investment analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $656.16.

Thermo Fisher Scientific Trading Down 1.0 %

TMO stock traded down $6.19 during midday trading on Monday, hitting $595.52. The company had a trading volume of 346,489 shares, compared to its average volume of 1,461,189. The company has a current ratio of 1.72, a quick ratio of 1.37 and a debt-to-equity ratio of 0.64. Thermo Fisher Scientific Inc. has a 52 week low of $415.60 and a 52 week high of $627.88. The stock’s 50 day moving average price is $607.99 and its 200 day moving average price is $584.23. The stock has a market cap of $227.49 billion, a price-to-earnings ratio of 37.33, a PEG ratio of 3.85 and a beta of 0.77.

Thermo Fisher Scientific (NYSE:TMO) last posted its earnings results on Wednesday, July 24th. The medical research company reported $5.37 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.13 by $0.24. The firm had revenue of $10.54 billion for the quarter, compared to analysts’ expectations of $10.50 billion. Thermo Fisher Scientific had a return on equity of 18.22% and a net margin of 14.69%. The business’s revenue was down 1.4% compared to the same quarter last year. During the same period in the previous year, the firm earned $5.15 earnings per share. As a group, equities research analysts expect that Thermo Fisher Scientific Inc. will post 21.72 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Thermo Fisher Scientific news, EVP Gianluca Pettiti sold 300 shares of the business’s stock in a transaction on Friday, July 26th. The stock was sold at an average price of $600.85, for a total value of $180,255.00. Following the sale, the executive vice president now directly owns 17,887 shares of the company’s stock, valued at approximately $10,747,403.95. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. In other Thermo Fisher Scientific news, EVP Gianluca Pettiti sold 300 shares of the business’s stock in a transaction on Friday, July 26th. The stock was sold at an average price of $600.85, for a total value of $180,255.00. Following the sale, the executive vice president now directly owns 17,887 shares of the company’s stock, valued at approximately $10,747,403.95. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CAO Joseph R. Holmes sold 860 shares of the business’s stock in a transaction on Friday, July 26th. The stock was sold at an average price of $611.03, for a total value of $525,485.80. Following the completion of the sale, the chief accounting officer now directly owns 1,814 shares in the company, valued at $1,108,408.42. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 23,084 shares of company stock valued at $14,094,292 over the last ninety days. Company insiders own 0.34% of the company’s stock.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.